IM Cannabis Corp(IMCC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 24 at 7:56 PM ET (Korea 9/25 08:56)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -62.81 | Insider Own | 11.78% | Shs Outstand | 0.6M | Perf Week | 82.76% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.6M | Perf Month | -2.57% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 1.94% | Short Float | 2.28% | Perf Quarter | -24.88% |
| Income | -0.01B | P/S | 0.06 | EPS this Y | - | Inst Trans | - | Short Ratio | 0 | Perf Half Y | -82.18% |
| Sales | 0.03B | P/B | - | EPS next 5Y | - | ROA | -54.47% | Short Interest | 0.01M | Perf YTD | -92.37% |
| Book/sh | -7.18 | P/C | 1.6 | EPS past 3/5Y | 74.93% 43.53% | ROE | -25089.74% | 52W High | -95.88% ($77.10) | Perf Year | -94.24% |
| Cash/sh | 1.99 | P/FCF | - | Sales past 3/5Y | -2.09% 27.02% | ROIC | - | 52W Low | 105.16% ($1.55) | Perf 3Y | -96.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -285.26% | Gross Margin | 12.57% | Volatility(W/M) | 62.35% 26% | Perf 5Y | -99.95% |
| Dividend TTM | - | EV/Sales | 0.31 | Sales Y/Y TTM | -11.91% | Oper. Margin | -25.87% | ATR (14) | 0.96 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.46 | EPS Q/Q | -396.75% | Profit Margin | -39.06% | RSI (14) | 52.22 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.56 | Sales Q/Q | -40.21% | SMA20 | 21.85% ($2.61) | Beta | 2.19 | Target Price | $180 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -1.57% ($3.23) | Rel Volume | 1.47 | Prev Close | $2.91 |
| Employees | 44 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -81.17% ($16.89) | Avg Volume(3M) | 2.63M | Price | $3.18 |
| IPO | 2020/5/20 | Option/Short | No/Yes | Trades | 18659 | Volume | 3,860,128 | Change | 9.28% |
Company
IMCC is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🍃 Medical cannabis platform. Operating in Israel and Germany. C4.7M revenue in 2025. 134% growth in Germany. Considering entry into the U.S. market.
Over the past 1 year, on the lower side
96% below its 1-year high.
IMCC has weak earning power
Review management risk carefully before investing
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -97.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 1.9%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $2M.
IMCC $2M PER -
TAK $59B PER -
TEVA $47B PER 67.1
HLN $41B PER 19.0
FAQ
What kind of company is IMCC?
IMCC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of IMCC?
The market cap of IMCC is approximately $2M, ranking 5,853 within its sector.
What is the 52-week high and low for IMCC?
IMCC has recorded a 52-week high of $77.10 and a low of $1.55.
